미국의 안드로겐성탈모증 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 판매채널별, 성별, 최종 용도별, 부문 예측(2025-2030년)
U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030
상품코드:1772261
리서치사:Grand View Research, Inc.
발행일:2025년 06월
페이지 정보:영문 80 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
미국의 안드로겐성탈모증 시장 동향 :
미국의 안드로겐성탈모증 시장은 2024년에는 9억 7,910만 달러에 달하며, 2025-2030년에 CAGR 6.6%로 성장할 것으로 예측됩니다.
안드로겐성탈모증(AGA)의 발병률 증가가 시장 성장의 원동력이 되고 있습니다. 가장 흔한 탈모증인 안드로겐성탈모증은 인구의 상당수가 앓고 있으며, 노화와 유전적 요인이 한몫을 하고 있습니다. 탈모에 대한 인식이 높아짐에 따라 치료를 원하는 사람들이 늘어나면서 시장이 확대되고 있습니다. 미국 국립의학도서관이 2023년 7월에 발표한 자료에 따르면 미국에서는 남성 약 5,000만 명, 여성 약 3,000만 명이 안드로겐성탈모증(AGA)을 앓고 있습니다.
또 다른 요인은 치료 옵션의 발전입니다. 이 시장에서는 외용액, 경구용 약물, 혈소판풍부혈장(PRP) 요법, 모발이식 수술과 같은 최소침습적 수술 등 혁신적인 치료법이 도입되고 있습니다. 제약사들도 보다 효과적이고 편리한 치료법을 개발하기 위해 연구개발에 투자하고 있으며, 다양한 소비자층을 끌어들이고 있습니다.
2025년 6월, 페라지 파마슈티컬스는 휴지기 모낭 줄기세포를 재활성화하여 탈모를 치료하는 국소 치료제 PP405의 임상 2a상 시험에서 좋은 결과를 얻었다고 발표했습니다. 이번 성과로 페라지는 안드로겐성탈모증 재생의학 분야의 선두주자로 자리매김하게 되었습니다.
The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).
Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.
The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.
U.S. Androgenetic Alopecia Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceuticals
Devices
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Homecare Settings
Dermatology Clinics
Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
Prescriptions
OTC
Gender Outlook (Revenue, USD Million, 2018 - 2030)
Male
Female
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.2.3. Sales Channel
1.2.4. Gender
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Sales Channel Outlook
2.2.4. Gender Outlook
2.3. Competitive Insights
Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Androgenetic Alopecia Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis
